... Herein we report a novel ALK fusion partner, the Linc00308/D21S2088E intergenic region, that conferred responsiveness to crizotinib in a patient with lung adenocarcinoma (LUAD)... Thus, we have provided proof that patients with advanced NSCLC harboring a Linc00308/D21S2088E intergenic region ALK may benefit from crizotinib, expanding the spectrum of ALK fusion variants to optimize treated strategy. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2020.03.009
Authors: Jian Zhang, Chang Zou, Chenzhi Zhou, Yifeng Luo, Qiong He, Yu Sun, Jianwen Zhou, Zunfu Ke
